Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital

Medicine

Volumn 81, Issue 6, 2002, Pages 425-433

  Garbino, Jorge ^a   Kolarova, Lenka ^a   Rohner, Peter ^a   Lew, Daniel ^a   Pichna, Peter ^a   Pittet, Didier ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; STEROID;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDIASIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FUNGEMIA; FUNGUS IDENTIFICATION; GROWTH; HOSPITAL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIFUNGAL AGENTS; CANDIDIASIS; CAUSALITY; COMORBIDITY; CROSS INFECTION; DRUG UTILIZATION; FEMALE; FLUCONAZOLE; FUNGEMIA; HOSPITAL MORTALITY; HOSPITALIZATION; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INFECTION CONTROL; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SWITZERLAND; TREATMENT OUTCOME;

EID: 0036841544     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200211000-00003     Document Type: Article

References (68)

1. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24: 1122-8, 1997.
2. Ang BS, Telenti A, King B, Steckelberg JM, Wilson WR. Candidemia from a urinary tract source: Microbiological aspects and clinical significance. Clin Infect Dis 17: 662-6, 1993.
3. Beck-Sague CM, Jarvis W. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 167: 1247-51, 1993.
4. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: A case-control study in adults without leukemia. Am J Med 87: 614-20, 1989.
5. Burchard KW, Minor LB, Slotman GL, Gann DS. Fungal sepsis in surgical patients. Arch Surg 118: 217-21, 1983.
6. Chryssanthou E. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: Comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27 - A reference method. J Clin Microbiol 39: 4181-3, 2001.
7. Cornfield J. A statistical problem arising from retrospective studies. In: Neyman J, ed. Proceedings of the Third Berkeley Symposium. Berkeley: University of California Press, 135-48, 1956.
8. Crislip MA, Edwards JE Jr. Candidiasis. Infect Dis Clin North Am 3: 103-33, 1989.
9. Dennis DL, Peterson CG, Fletcher WS. Candida septicemia in the severely traumatized patient. J Trauma 8: 177-85, 1968.
10. Diamond RD, Krzesicki R, Jao W. Damage to pseudohyphal forms of Candida albicans by neutrophils in the absence of serum in vitro. J Clin Invest 61: 349-59, 1978.
11. Doebbeling BN, Pfaller MA, Hollis RJ, Boyken LD, Pignatari AC, Herwaldt LA, Wenzel R. Restriction endonuclease analysis of Staphylococcus aureus plasmid DNA from three continents. Eur J Clin Microbiol Infect Dis 11: 4-8, 1992.
12. Dom GL, Smith K. New centrifugation blood culture device. J Clin Microbiol 7: 52-4, 1978.
13. Dunne WM. Blood Cultures III. Washington, DC: American Society of Microbiology. 1997.
14. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 29: 239-44, 1999.
15. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet 355: 1864-8, 2000.
16. Eubanks PJ, de Virgilio C, Klein S, Bongard F. Candida sepsis in surgical patients. Am J Surg 166: 617-9, 1993.
17. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15: 414-21, 1992.
18. Garbino J, Pittet D. Candida infections in the ICU. Clin Intensive Care 8: 187-200, 1997.
19. Garbino J, Romand JA, Suter PM, Pittet D. Use of antibiotics in patients receiving intensive care. Clin Intensive Care 9: 25-35, 1998.
20. Harbarth S, Martin Y, Rohner P, Henry N, Auckenthaler R, Pittet D. Effect of delayed infection control measures on a hospital outbreak of methicillin-resistant Staphylococcus aureus. J Hosp Infect 46: 43-9, 2000.
21. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy. Rev Infect Dis 7: 646-55, 1985.
22. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 20: 1526-30, 1995.
23. Jarvis WR, Edwards JR, Culver DH, Hughes JM, Horan T, Emori TG, Banerjee S, Tolson J, Henderson T, Gaynes RP, Martone WJ, and the National Nosocomial Infections Surveillance System. Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Am J Med 91: 185S-91S, 1991.
24. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, Baughman WS, Reingold AL, Rothrock GA, Pfaller MA, Pinner RW, Hajjeh RA. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 29: 1164-70, 1999.
25. Karp JE, Merz WG, Charache P. Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia. Rev Infect Dis 13: 592-9, 1991.
26. Klein JJ, Watanakunakorn C. Hospital-acquired fungeima. Its natural course and clinical significance. Am J Med 67: 51-8, 1979.
27. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 11: 379-90, 1989.
28. Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet 1: 598-9, 1969.
29. Kullberg BJ, Voss A. [The changing pattern of Candida infections: Different species and increased resistance.] Ned Tijdschr Geneeskd 140: 148-51, 1996.
30. Maksymiuk AW, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP. Systemic candidiasis in cancer patients. Am J Med 77(4D): 20-7, 1984.
31. McGinnis MR, Sigler L, Rinaldi MG. Some medically important fungi and their common synonyms and names of uncertain application. Clin Infect Dis 29: 728-30, 1999.
32. Meis JF, Ruhnke M, de Pauw BE, Odds FC, Siegert W, Verweij PE. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 5: 150-3, 1999.
33. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungeima in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med 71: 363-70, 1981.
34. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 14(Suppl 1): S120-S125, 1992.
35. Nassoura Z, Ivatury RR, Simon RJ, Jabbour N, Stahl WM. Candiduria as an early marker of disseminated infection in critically ill surgical patients: The role of fluconazole therapy. J Trauma 35: 290-4, 1993.
36. Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW. Fluconazole and Candida krusei fungemia. N Engl J Med 325: 1315, 1991.
37. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 11: 287-91, 1992.
38. Pfaller MA. Epidemiology and control of fungal infections. Clin Infect Dis 19(Suppl 1): S8-13, 1994.
39. Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 35: 19-25, 1999.
40. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 36: 1886-9, 1998.
41. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 44: 747-51, 2000.
42. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 30: 121-9, 1998.
43. Pfaller MA, Messer SA, Hollis RJ. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn Microbiol Infect Dis 20: 127-33, 1994.
44. Pittet D, Garbino J. Fungal infections in the critically ill. Curr Opin Crit Care 1: 369-80, 1995.
45. Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S, Perneger TV. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 356: 1307-12, 2000.
46. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections. A six year validated, population-based model. Clin Infect Dis 24: 1068-78, 1997.
47. Pittet D, Monod M, Filthuth I, Frenk E, Suter PM, Auckenthaler R. Contour-clamped homogeneous electric field gel electrophoresis as a powerful epidemiologic tool in yeast infections. Am J Med 91: 256S-263S, 1991.
48. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220: 751-8, 1994.
49. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: Excess length of stay, extra costs, and attributable mortality. JAMA 271: 1598-601, 1994.
50. Pittet D, Wenzel RP. Nosocomial bloodstream infections: Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 155: 1177-84, 1995.
51. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 38: 1422-7, 1994.
52. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 28: 2733-8, 1990.
53. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 27: 781-8, 1998.
54. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331: 1325-30, 1994.
55. Richards KE, Pierson CL, Bucciarelli L, Feller I. Monilial sepsis in the surgical patient. Surg Clin North Am 52: 1399-406, 1972.
56. Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 13: 211-5, 1991.
57. Rohner P, Pepey B, Auckenthaler R. Advantage of combining resin with lytic BACTEC blood culture media. J Clin Microbiol 35: 2634-8, 1997.
58. Verduyn Lunel FM, Meis JF, Voss A. Nosocomial fungal infections: Candidemia. Diagn Microbiol Infect Dis 34: 213-20, 1999.
59. Voss A, Kluytmans JA, Koeleman JG, Spanjaard L, Vandenbroucke-Grauls CM, Verbrugh HA, Vos MC, Weersink AY, Hoogkamp-Korstanje JA, Meis JF. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis 15: 909-12, 1996.
60. Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis JF. Candidemia in intensive care unit patients: Risk factors for mortality. Infection 25: 8-11, 1997.
61. Weinstein MP, Reller LB, Murphy JR, Lichtenstein KA. The clinical significance of positive blood cultures: A comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 5: 35-53, 1983.
62. Wenzel RP. Nosocomial candidemia: Risk factors and attributable mortality. Clin Infect Dis 20: 1531-4, 1995.
63. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 149: 2349-53, 1989.
64. Wey SB, Motomi M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148: 2642-5, 1988.
65. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 20: 115-25, 1995.
66. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325: 1274-7, 1991.
67. Yamamura DL, Rotstein C, Nicolle LE, Ioannou S. Candidemia at selected Canadian sites: Results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. CMAJ 160: 493-9, 1999.
68. Young RC, Bennett JE, Geelhoed GW, Levine AS. Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med 80: 605-12, 1974.